I21 I22 I60 I61 I62 I63 I64 I65 I66 I67 I68 I69 G81 G82 G83 S06 I50
Conditions
Interventions
Group 1: The intervention group (IG) is formed by voluntary participants (insured persons living in Saxony-Anhalt) of the intervention programme. The patient coordinators receive optimized and needs-b
Sponsors
IKK gesund plus
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: The target group of the intervention, which began on 01.04.2018, are insured persons of the IKK gesund plus who have reached the age of 18 and are treated as in-patients with one of the main (index) diagnoses such as myocardial infarction, cerebrovascular disease or cerebral palsy and other paralysis syndromes as well as intracranial injuries: I21 Acute myocardial infarction I22 Recurrent myocardial infarction I50 Heart failure (in combination with admission reason "XX07" emergency) I60 Subararchnoid haemorrhage I61 Intracerebral haemorrhage I62 Other non-traumatic intracranial haemorrhages I63 Cerebral infarction I64 Stroke, not referred to as haemorrhage or infarction I65 Occlusion and stenosis of precerebral arteries without resulting cerebral infarction I66 Occlusion and stenosis of cerebral arteries without resulting cerebral infarction I67 Other cerebrovascular diseases I68 Cerebrovascular disorders in elsewhere classified diseases I69 Consequences of cerebrovascular disease G81 Hemiparesis and hemiplegia G82 Paraparesis and paraplegia, tetraparesis and tetraplegia G83 Other paralysis syndromes S06 Intracranial injury (exception: without S06.0)
Exclusion criteria
Exclusion criteria: /
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Five hypotheses are examined: 1. IKK IVP reduces the time between discharge from inpatient treatment or rehabilitation and the start of remedy supply (process level). 2. IKK IVP increases the proportion of patients with guideline-based medication (process level). 3. IKK IVP reduces the risk of re-events and deaths (result level). 4. IKK IVP reduces the risk of need for long-term care or assistance (result level). 5. IKK IVP increases patients' quality of life (result level). The validity of hypotheses 1 to 4 can be evaluated using claims data from the statutory health insurance funds because they address scope, type, and amount of medical services. In Module 1, standardized claims data from the two statutory health insurance funds is used. The obligation to evaluate is laid down in the Social Code (SGB) V; the underlying data of the statutory health insurance funds is regulated in section 295 SGB V pp. In detail, this includes data on inpatient care (sect. 301 SGB V), services for medical rehabilitation as well as data about the supply of medicines (sect. 300 SGB V), therapeutic appliances and aids (sect. 302 SGB V). Data concerning the need for long-term care also will be used. In order to map the transition from inpatient to outpatient (follow-up) care after an acute event or rehabilitation, performance data from outpatient care (sect. 295 SGB V) is also used, with supplementary data on incapacity for work and reduced earning capacity for the subgroup of employed patients. Module 2 aims to measure the quality of life (Hypothesis 4) and the assistance needs or limitations in everyday activities of patients suffering from one of the index diseases (Hypothesis 5). An interview will take place ten weeks after the occurrence of the disease and thus after the end of the acute treatment as well as a second time six months after discharge from hospital. The questionnaire consists of the Short-Form12 Health Survey Version 2 of the Socio-Economic Panel (SF12v2 of SOEP) to | — |
Countries
Germany
Contacts
Public ContactAndreas Köhler
IKK gesund plus
Outcome results
None listed